43 results on '"Dangond, Fernando"'
Search Results
2. Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study (4131)
3. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets (1942)
4. Pharmacodynamic Biomarkers of Interferon β-1a: Assessment in Patients Receiving Long-Term Treatment with Subcutaneous Interferon β-1a (691)
5. Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial (P3.2-061)
6. Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study (S56.004)
7. The effect of cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLE-MS study (P3.2-101)
8. Cladribine tablets added to IFN-β in active relapsing MS
9. Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg (P3.407)
10. Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)
11. Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)
12. Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study (P6.360)
13. Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) (P6.349)
14. Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351)
15. Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353)
16. Cladribine tablets in the treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program (P5.394)
17. Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379)
18. Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058)
19. Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of the EVIDENCE Study (P6.189)
20. Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study (P2.114)
21. Interferon β-1a SC tiw Reduces Mild to Moderate and Moderate to Severe Relapses and Disease Activity over 1 Year in Patients with Relapsing MS: Post Hoc Analyses of PRISMS Data (P3.036)
22. Efficacy of Cladribine Tablets in ORACLE Study Patients Who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline (P3.035)
23. Predictive Value of 6-Month T2 and Enhancing Lesions Among Patients with RRMS Receiving Interferon β-1a Subcutaneously Thrice Weekly or Placebo: Post Hoc Analyses of PRISMS Data (P1.401)
24. Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095)
25. Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)
26. Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028)
27. MRI Frequency and No Evidence of Disease Activity Status Among Patients with RRMS Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of EVIDENCE (P6.190)
28. Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
29. Early Onset and Predictive Value of MRI Measures among Patients Receiving Interferon Beta-1a SC tiw for RRMS: Post Hoc Analyses of PRISMS-2 Data (P7.254)
30. No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw versus Interferon Beta-1a IM qw: Subgroup Analyses of the EVIDENCE Study (P7.271)
31. Early Effects of Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw on MRI Outcomes in Patients with Relapsing MS in the EVIDENCE Study (P7.257)
32. No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw in the EVIDENCE Study (P7.220)
33. 1-Year Efficacy and Tolerability Results for IFN Beta-1a SC tiw Treatment and Predictive Value of 6-Month MRI: Exploratory Analysis of PRISMS Data in Patients with RRMS (P7.242)
34. Relationship between Cognitive Status and Perception of Ease of Use of an Electronic Autoinjector for Subcutaneous Interferon Beta-1a (P3.225)
35. Development of Chronic Black Holes (CBH) Predicts Long Term Disability: Post-hoc Analysis of Magnetic Resonance Imaging (MRI) Data in the PRISMS Study (P7.251)
36. Quality of life perceptions correlate with longitudinal clinical relapse reduction metrics in patients treated with subcutaneous interferon beta-1a given three times a week. (P1.113)
37. Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146)
38. Associations Between Changes in Ferritin Levels and Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a (P6.115)
39. Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (P3.147)
40. Changes in Immunological Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta-1a (P4.132)
41. Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240)
42. Early and Consistent Reduction in Relapses among Patients with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of PRISMS Data (P3.182)
43. Interferon beta-1a Treatment Inhibits Th1- and Th17-Cell Responses in Patients with Relapsing–Remitting Multiple Sclerosis (P05.144)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.